News Evotec SE CBOE

Stocks

0IRF

DE0005664809

Biotechnology & Medical Research

Market Closed - CBOE 09:00:00 11/09/2026 pm IST			5-day change	1st Jan Change
3.217 ^EUR	0.00%		0.00%	-40.37%

09/09	Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment	MT
09/09	Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy	MT

All News

Mentions Relevance

09/09	Evotec Initiates Phase 1 Trial of Potential Smallpox, Mpox Treatment	MT
09/09	Evotec Commences Early-stage Study of Potential Orthopoxvirus Therapy	MT
09/09	Just – Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies	EQ
02/09	Evotec, Plectonic Launch Research Collaboration on New T-Cell Approaches for Solid Tumors	MT
02/09	Evotec, Plectonic Biotech Partner on Research of Novel Immunotherapy for Solid Tumors	MT
02/09	Evotec SE And Plectonic Biotech Enter Research Collaboration To Explore New Generation Of T-Cell-Engaging Approaches For Solid Tumors	CI
02/09	Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors	EQ
13/08	Evotec's final first-half results once again spook investors	DP
13/08	Evotec SE Reports Earnings Results for the Half Year Ended June 30, 2026	CI
13/08	Evotec SE : Gets a Buy rating from RBC	ZD
13/08	Evotec : Half-year report 2026, PDF (H1 Report 2026 English)	PU
13/08	Evotec : Half-year report 2026, PDF (Interim Statement H1 2026 English)	PU
13/08	Evotec Se Announces Camilla Macapili Languille Step Down as Supervisory Board, Effective August 7, 2026	CI
13/08	Evotec Se Reaffirms Earnings Guidance for the Full-Year 2026	CI
06/08	Evotec, Odyssey Therapeutics Partner to Develop Autoimmune, Inflammatory Disease Treatments	MT
06/08	Evotec, Odyssey Therapeutics Team Up on Autoimmune, Inflammatory Disease Treatment Research	MT
06/08	Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases	EQ
06/08	Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases	PU
04/08	Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168	CI
03/08	Niagen Bioscience, Evotec to Advance Preclinical Development of NB4168	MT
16/07	Berenberg Downgrades Evotec to Hold From Buy, Cuts Price Target to EUR3.60 From EUR9.40	MT
16/07	EVOTEC : Deutsche Bank reaffirms its Neutral rating	ZD
16/07	EVOTEC : Reduced to Neutral by Berenberg	ZD
16/07	Berenberg downgrades Evotec to 'Hold', target cut to €3.60	DP
16/07	Evotec Shares Fall After TD Cowen Downgrade	MT